PMID- 24868024
OWN - NLM
STAT- MEDLINE
DCOM- 20140815
LR  - 20221207
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 32
IP  - 19
DP  - 2014 Jul 1
TI  - Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of 
      HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, 
      phase III study.
PG  - 2039-49
LID - 10.1200/JCO.2013.53.6136 [doi]
AB  - PURPOSE: In Asian countries, paclitaxel once per week is used as second-line 
      treatment in advanced gastric cancer, including human epidermal growth factor 
      receptor 2 (HER2) -positive tumors. The role of anti-HER2 agents, including 
      lapatinib, in this setting and population is unclear. PATIENTS AND METHODS: TyTAN 
      was a two-part, parallel-group, phase III study in Asian patients. An open-label, 
      dose-optimization phase (n = 12) was followed by a randomized phase (n = 261), in 
      which patients who were HER2 positive by fluorescence in situ hybridization 
      (FISH) received lapatinib 1,500 mg once per day plus once-per-week paclitaxel 80 
      mg/m(2) or paclitaxel alone. The primary end point was overall survival (OS). 
      Secondary end points included progression-free survival (PFS), time to 
      progression (TTP), overall response rate (ORR), time to response, response 
      duration, and safety. Analyses were based on immunohistochemistry (IHC) and 
      gastrectomy status, prior trastuzumab therapy, and regional subpopulations. 
      RESULTS: Median OS was 11.0 months with lapatinib plus paclitaxel versus 8.9 
      months with paclitaxel alone (P = .1044), with no significant difference in 
      median PFS (5.4 v 4.4 months) or TTP (5.5 v 4.4 months). ORR was higher with 
      lapatinib plus paclitaxel versus paclitaxel alone (odds ratio, 3.85; P < .001). 
      Better efficacy with lapatinib plus paclitaxel was demonstrated in IHC3+ compared 
      with IHC0/1+ and 2+ patients and in Chinese compared with Japanese patients. A 
      similar proportion of patients experienced adverse events with each treatment 
      (lapatinib plus paclitaxel, 100% v paclitaxel alone, 98%). CONCLUSION: Lapatinib 
      plus paclitaxel demonstrated activity in the second-line treatment of patients 
      with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly 
      improve OS in the intent-to-treat population.
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Satoh, Taroh
AU  - Satoh T
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Xu, Rui-Hua
AU  - Xu RH
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Chung, Hyun Cheol
AU  - Chung HC
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Sun, Guo-Ping
AU  - Sun GP
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Doi, Toshihiko
AU  - Doi T
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Xu, Jian-Ming
AU  - Xu JM
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Tsuji, Akihito
AU  - Tsuji A
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Omuro, Yasushi
AU  - Omuro Y
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Li, Jin
AU  - Li J
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Wang, Jin-Wan
AU  - Wang JW
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Miwa, Hiroto
AU  - Miwa H
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Qin, Shu-Kui
AU  - Qin SK
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Chung, Ik-Joo
AU  - Chung IJ
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Yeh, Kun-Huei
AU  - Yeh KH
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Feng, Ji-Feng
AU  - Feng JF
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Mukaiyama, Akihira
AU  - Mukaiyama A
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Kobayashi, Mikiro
AU  - Kobayashi M
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Ohtsu, Atsushi
AU  - Ohtsu A
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Bang, Yung-Jue
AU  - Bang YJ
AD  - Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and 
      Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi 
      Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and 
      Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro 
      Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, 
      Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, 
      First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 
      Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and 
      Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University 
      Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; 
      Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of 
      China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of 
      Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; 
      Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South 
      Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan. 
      bangyj@snu.ac.kr.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140527
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (Lapatinib)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Area Under Curve
MH  - *Asian People/genetics/statistics & numerical data
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lapatinib
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Paclitaxel/administration & dosage/*therapeutic use
MH  - Pilot Projects
MH  - Quinazolines/administration & dosage
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Stomach Neoplasms/chemistry/*drug therapy/epidemiology/pathology
MH  - Treatment Outcome
EDAT- 2014/05/29 06:00
MHDA- 2014/08/16 06:00
CRDT- 2014/05/29 06:00
PHST- 2014/05/29 06:00 [entrez]
PHST- 2014/05/29 06:00 [pubmed]
PHST- 2014/08/16 06:00 [medline]
AID - JCO.2013.53.6136 [pii]
AID - 10.1200/JCO.2013.53.6136 [doi]
PST - ppublish
SO  - J Clin Oncol. 2014 Jul 1;32(19):2039-49. doi: 10.1200/JCO.2013.53.6136. Epub 2014 
      May 27.